Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 311 participants.

Also called NCT01392677

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 311 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01392677
Other papers using this trial's data
  • Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial Diabetes care, 2015-03 DOI, PubMed 25592197

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada, Czechia, Germany, Poland, Slovakia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01392677. Randomized; quadruple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2013-12-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Condition
Type 2 Diabetes Mellitus
Condition
High HbA1c Level
Condition
Inadequate Glycaemic Control
Intervention (Drug)
dapagliflozin
Intervention (Drug)
placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01392677
Content hash
0154aeac30837cc9939f62ae6cdbed7d6335c054499b69941cf94fcdff1b8d2d